Fundació de Recerca Clínic Barcelona – Instituto de Investigaciones Biomédicas August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain

Representing the Coordinator of the consortium, it is a research center of excellence that deals with diseases of high prevalence, morbidity and mortality.  FCRB-IDIBAPS is the result of the integration in 2023 of the Hospital Clínic Foundation for Biomedical Research (FCRB), created in 1989, and the consortium August Pi i Sunyer Biomedical Research Institute, created in 1996. It is a nonprofit foundation with a board of governors representing the Catalan Government departments of Health and of Research and Universities, Hospital Clínic de Barcelona, and Universitat de Barcelona.

The PI of the node coordinator of THERAVINFO is Patricia Pérez-Galán, head of the group of “Microenvironment in lymphoma pathogenesis and therapy” at FRCB-IDIBAPS, holds extensive experience in the study of lymphoma microenvironment and derived targeted therapies, together with the development of patient-derived ex vivo models.

---

---

Fundació de Recerca Clínic Barcelona – Hospital Clinic de Barcelona (FRCB-HCB), Barcelona, Spain

The HCB is a university hospital founded in the year 1906 and it belongs to the network of Hospitals of Public Utility of Catalonia (RHUP). It covers practically all medical and surgical specialties and develops activities in the fields of Assistance, Research and Teaching, either directly or through linked companies. HCB is a reference and pioneering hospital in Catalonia and Spain. The hospital acts as a community hospital, being the main public supplier for its zone of reference in the city of Barcelona, with a population of 540,000 inhabitants and, at the same time, as a tertiary hospital of high complexity, developing lines of activity for patients not only from Catalonia, but also from all over Spain, and even at the international level.  In order to ensure continuity of care and the integral provision of health services, Hospital Clínic participates in the management of primary care centers, develops mental health activities and establishes alliances with other centers to cover the public health needs of their patients. HCB is a reference and pioneering hospital in Catalonia and SPAIN. HCB is a partner in the Faculty of Medicine of the University of Barcelona.

The PI of this node is Dolors Colomer, Head of the Hematopathology Unit at HCB, will be in charge of providing samples from NHL patients. The departments of Hematology and Pathology will provide the associated clinical-pathological data. Moreover, Dr. Colomer is also the head of “Experimental therapeutics in lymphoid neoplasia” at FRCB-IDIBAPS.

---

---

CIMA Universidad de Navarra, Pamplona, Spain

The Universidad de Navarra is a leading institution in Spain, known for its strong emphasis on scientific research and education. Located in Pamplona, it offers state-of-the-art facilities and a vibrant academic environment. The university excels in biomedicine, with the Center for Applied Medical Research (CIMA) conducting pioneering studies in oncology, neuroscience, and cardiovascular diseases. The School of Sciences provides rigorous programs in various disciplines, promoting interdisciplinary collaboration through institutes like the Institute of Tropical Health (ISTUN) and the Institute for Culture and Society (ICS). The university’s holistic approach integrates scientific discoveries with real-world applications, fostering innovation and sustainability. It offers extensive research opportunities, internships, and industry collaborations, preparing students to become leaders in the scientific community.

The PI of this node is Sergio Roa Gómez a distinguished researcher leading the Linfomas team at the University of Navarra’s CIMA and the Department of Biochemistry and Genetics leading Linfomas team. Holding a PhD in Molecular Medicine from the University of Salamanca, he has been recognized with several awards for his academic excellence. His research primarily focuses on the genetic and molecular mechanisms underlying lymphomas, with a particular interest in developing novel therapeutic strategies. Dr. Roa is also involved in various interdisciplinary projects, leveraging advanced technologies to improve cancer treatment outcomes.

---

---

Université de Toulouse III Paul Sabatier – Centre de Recherche en Cancerologie de Toulouse (CRCT), France

The Université de Toulouse III Paul Sabatier is a prominent research and education institution in France, particularly noted for its contributions to aerospace, biotechnology, and environmental science. Located in Toulouse, it provides state-of-the-art facilities and promotes interdisciplinary research and innovation. The university’s Faculty of Science and Engineering offers comprehensive programs in mathematics, physics, chemistry, and computer science. The Centre de Recherche en Cancerologie de Toulouse (CRCT) is integrated into the Oncopôle, a regional and international hub for cancer research and patient care. CRCT emphasizes a multidisciplinary approach, combining research, care, and teaching to address cancer effectively.

The PI of this node Christine Bezombes is integrated in the team of Dr. Camile Laurent, NoLymIT has holds extensive experience in the study of the NHL biology, the mechanisms of “immunoescape” and in the characterization of the mechanisms of action of new therapeutic strategies both in 3D models and animal models.

---

---

Centre Hospitalier Universitaire de Toulouse (CHUT), France

The Centre Hospitalier Universitaire de Toulouse (CHUT) provides highly specialized medical and surgical services, emergency care, and innovative alternatives to traditional hospitalization, such as ambulatory activities and telemedicine. As a community hospital, CHUT ensures universal access to healthcare and participates in public health initiatives, prevention, and health education. It is a partner of the Faculties of Medicine, Dentistry, and Pharmacy at Université de Toulouse III Paul Sabatier. In clinical research, CHUT actively contributes to advancements in medical and pharmaceutical sciences in collaboration with various academic and research institutions.

The PI of this node is Prof. Camille Laurent, a pathologist at the Centre Hospitalier Universitaire de Toulouse (CHUT) and head of the NoLymIT team. She is responsible for providing and characterizing samples from patients with non-Hodgkin lymphoma (NHL). Dr. Laurent has extensive experience in the molecular characterization of rare lymphomas and the identification of biomarkers. Her research also focuses on the mechanisms by which lymphoma cells evade immune effector cells.